Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
2 Acute myeloid leukemia 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
3 Adherens junction 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
4 Adipocytokine signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
5 Adipocytokine signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
6 Adipocytokine signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
7 Adipocytokine signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
8 Adipocytokine signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
9 African trypanosomiasis 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
10 African trypanosomiasis 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
11 African trypanosomiasis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
12 African trypanosomiasis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
14 AGE-RAGE signaling pathway in diabetic complications 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
15 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
16 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
17 AGE-RAGE signaling pathway in diabetic complications 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
18 Alanine, aspartate and glutamate metabolism 💬
4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
19 Alcoholic liver disease 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
20 Alcoholic liver disease 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
21 Alcoholic liver disease 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
22 Alcoholic liver disease 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
23 Aldosterone synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
24 Allograft rejection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
25 Allograft rejection 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
26 Allograft rejection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
27 Alzheimer disease 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
28 Alzheimer disease 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
29 Alzheimer disease 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
30 Alzheimer disease 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
31 Alzheimer disease 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
32 Alzheimer disease 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
33 Alzheimer disease 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
34 Alzheimer disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
35 Alzheimer disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
36 Amoebiasis 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
37 Amoebiasis 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
38 Amoebiasis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
39 Amoebiasis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
40 AMPK signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
41 AMPK signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
42 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
43 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
44 Amyotrophic lateral sclerosis 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
45 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
46 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
47 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
48 Amyotrophic lateral sclerosis 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
49 Amyotrophic lateral sclerosis 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
50 Antifolate resistance 💬
2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
51 Antifolate resistance 💬
2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
52 Antifolate resistance 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
53 Antifolate resistance 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
54 Antifolate resistance 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
55 Antifolate resistance 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
56 Antigen processing and presentation 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
57 Antigen processing and presentation 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
58 Antigen processing and presentation 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
59 Apelin signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
60 Apelin signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
61 Apoptosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
62 Apoptosis 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
63 Apoptosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
64 Asthma 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
65 Asthma 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
66 Asthma 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
67 Autophagy - animal 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
68 Autophagy - animal 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
69 Autophagy - other 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
70 Autophagy - other 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
71 B cell receptor signaling pathway 💬
1件: BTK 💬 D11422 💬 Zanubrutinib 2件: 300, 331 💬
72 beta-Alanine metabolism 💬
3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
73 Biosynthesis of cofactors 💬
2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
74 Biosynthesis of cofactors 💬
2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
75 Bladder cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
76 Bladder cancer 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
77 Breast cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
78 Breast cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
79 Breast cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
80 Butanoate metabolism 💬
4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
81 C-type lectin receptor signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
82 C-type lectin receptor signaling pathway 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
83 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
84 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
85 Calcium signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
86 Calcium signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
87 Calcium signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
88 Cellular senescence 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
89 Cellular senescence 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
90 Cellular senescence 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
91 Cellular senescence 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
92 Central carbon metabolism in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
93 Central carbon metabolism in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
94 Central carbon metabolism in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
95 Chagas disease 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
96 Chagas disease 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
97 Chagas disease 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
98 Chagas disease 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
99 Chemical carcinogenesis - reactive oxygen species 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
100 Chemical carcinogenesis - reactive oxygen species 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
101 Chemical carcinogenesis - receptor activation 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
102 Chemical carcinogenesis - receptor activation 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
103 Chemical carcinogenesis - receptor activation 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
104 Chemical carcinogenesis - receptor activation 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
105 Choline metabolism in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
106 Choline metabolism in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
107 Choline metabolism in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
108 Circadian entrainment 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
109 Colorectal cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
110 Colorectal cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
111 Colorectal cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
112 Coronavirus disease - COVID-19 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
113 Coronavirus disease - COVID-19 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
114 Coronavirus disease - COVID-19 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
115 Coronavirus disease - COVID-19 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
116 Coronavirus disease - COVID-19 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
117 Coronavirus disease - COVID-19 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
118 Cortisol synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
119 Cushing syndrome 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
120 Cushing syndrome 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
121 Cytokine-cytokine receptor interaction 💬
1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
122 Cytokine-cytokine receptor interaction 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
123 Cytokine-cytokine receptor interaction 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
124 Cytokine-cytokine receptor interaction 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
125 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
126 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
127 Cytosolic DNA-sensing pathway 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
128 Cytosolic DNA-sensing pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
129 Diabetic cardiomyopathy 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
130 Diabetic cardiomyopathy 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
131 Dilated cardiomyopathy 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
132 Dilated cardiomyopathy 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
133 Dilated cardiomyopathy 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
134 EGFR tyrosine kinase inhibitor resistance 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
135 EGFR tyrosine kinase inhibitor resistance 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
136 EGFR tyrosine kinase inhibitor resistance 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
137 EGFR tyrosine kinase inhibitor resistance 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
138 EGFR tyrosine kinase inhibitor resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
139 EGFR tyrosine kinase inhibitor resistance 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
140 EGFR tyrosine kinase inhibitor resistance 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
141 Endocrine resistance 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
142 Endocrine resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
143 Endocrine resistance 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
144 Endocytosis 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
145 Endometrial cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
146 Epithelial cell signaling in Helicobacter pylori infection 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
147 Epstein-Barr virus infection 💬
1件: BTK 💬 D11422 💬 Zanubrutinib 2件: 300, 331 💬
148 Epstein-Barr virus infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
149 Epstein-Barr virus infection 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
150 Epstein-Barr virus infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
151 Epstein-Barr virus infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
152 ErbB signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
153 ErbB signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
154 ErbB signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
155 Estrogen signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
156 Fc epsilon RI signaling pathway 💬
1件: BTK 💬 D11422 💬 Zanubrutinib 2件: 300, 331 💬
157 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
158 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
159 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
160 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
161 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
162 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
163 Fluid shear stress and atherosclerosis 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
164 Focal adhesion 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
165 Focal adhesion 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
166 Folate biosynthesis 💬
2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
167 Folate biosynthesis 💬
2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
168 FoxO signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
169 FoxO signaling pathway 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
170 FoxO signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
171 GABAergic synapse 💬
3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
172 Gap junction 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
173 Gap junction 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
174 Gap junction 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
175 Gastric cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
176 Gastric cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
177 Gastric cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
178 Glioma 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
179 Glioma 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
180 Glioma 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
181 GnRH secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
182 GnRH signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
183 Graft-versus-host disease 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
184 Graft-versus-host disease 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
185 Graft-versus-host disease 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
186 Graft-versus-host disease 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
187 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
188 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
189 Hematopoietic cell lineage 💬
1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
190 Hematopoietic cell lineage 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
191 Hematopoietic cell lineage 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
192 Hematopoietic cell lineage 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
193 Hematopoietic cell lineage 💬
1件: MS4A1 💬 D02994 💬 Rituximab 49件:  6 , 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
194 Hematopoietic cell lineage 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
195 Hematopoietic cell lineage 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
196 Hepatitis B 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
197 Hepatitis B 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
198 Hepatitis B 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
199 Hepatitis B 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
200 Hepatitis C 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
201 Hepatitis C 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
202 Hepatitis C 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
203 Hepatitis C 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
204 Hepatocellular carcinoma 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
205 Hepatocellular carcinoma 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
206 Hepatocellular carcinoma 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
207 Herpes simplex virus 1 infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
208 Herpes simplex virus 1 infection 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
209 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
210 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
211 Herpes simplex virus 1 infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
212 Herpes simplex virus 1 infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
213 HIF-1 signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
214 HIF-1 signaling pathway 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
215 HIF-1 signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
216 HIF-1 signaling pathway 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
217 HIF-1 signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
218 HIF-1 signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
219 HIF-1 signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
220 Human cytomegalovirus infection 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
221 Human cytomegalovirus infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
222 Human cytomegalovirus infection 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
223 Human cytomegalovirus infection 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
224 Human cytomegalovirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
225 Human cytomegalovirus infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
226 Human cytomegalovirus infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
227 Human cytomegalovirus infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
228 Human cytomegalovirus infection 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
229 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
230 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
231 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
232 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
233 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
234 Human papillomavirus infection 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
235 Human papillomavirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
236 Human papillomavirus infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
237 Human papillomavirus infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
238 Human papillomavirus infection 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
239 Human papillomavirus infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
240 Human papillomavirus infection 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
241 Human T-cell leukemia virus 1 infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
242 Human T-cell leukemia virus 1 infection 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
243 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
244 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
245 Huntington disease 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
246 Huntington disease 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
247 Huntington disease 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
248 Huntington disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
249 Huntington disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
250 Hypertrophic cardiomyopathy 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
251 Hypertrophic cardiomyopathy 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
252 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
253 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
254 IL-17 signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
255 IL-17 signaling pathway 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
256 IL-17 signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
257 IL-17 signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
258 Inflammatory bowel disease 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
259 Inflammatory bowel disease 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
260 Inflammatory bowel disease 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
261 Inflammatory bowel disease 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
262 Influenza A 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
263 Influenza A 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
264 Influenza A 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
265 Influenza A 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
266 Insulin resistance 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
267 Insulin resistance 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
268 Insulin resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
269 Insulin resistance 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
270 Insulin resistance 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
271 Insulin resistance 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
272 Insulin signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
273 Insulin signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
274 Intestinal immune network for IgA production 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
275 Intestinal immune network for IgA production 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
276 JAK-STAT signaling pathway 💬
1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
277 JAK-STAT signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
278 JAK-STAT signaling pathway 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
279 JAK-STAT signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
280 JAK-STAT signaling pathway 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
281 JAK-STAT signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
282 JAK-STAT signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
283 Kaposi sarcoma-associated herpesvirus infection 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
284 Kaposi sarcoma-associated herpesvirus infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
285 Kaposi sarcoma-associated herpesvirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
286 Kaposi sarcoma-associated herpesvirus infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
287 Kaposi sarcoma-associated herpesvirus infection 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
288 Legionellosis 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
289 Legionellosis 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
290 Legionellosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
291 Legionellosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
292 Leishmaniasis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
293 Leishmaniasis 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
294 Leishmaniasis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
295 Lipid and atherosclerosis 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
296 Lipid and atherosclerosis 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
297 Lipid and atherosclerosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
298 Lipid and atherosclerosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
299 Longevity regulating pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
300 Longevity regulating pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
301 Longevity regulating pathway - multiple species 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
302 Longevity regulating pathway - multiple species 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
303 Malaria 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
304 Malaria 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
305 Malaria 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
306 Malaria 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
307 MAPK signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
308 MAPK signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
309 MAPK signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
310 MAPK signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
311 MAPK signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
312 MAPK signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
313 Measles 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
314 Measles 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
315 Melanoma 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
316 Metabolic pathways 💬
4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
317 Metabolic pathways 💬
2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
318 Metabolic pathways 💬
2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
319 MicroRNAs in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
320 MicroRNAs in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
321 MicroRNAs in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
322 MicroRNAs in cancer 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
323 mTOR signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
324 mTOR signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
325 mTOR signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
326 mTOR signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
327 mTOR signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
328 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
329 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
330 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
331 Necroptosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
332 Necroptosis 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
333 Necroptosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
334 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 D00473 💬 Prednisone 48件:  2 ,  6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬
335 Neutrophil extracellular trap formation 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
336 Neutrophil extracellular trap formation 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
337 NF-kappa B signaling pathway 💬
1件: BTK 💬 D11422 💬 Zanubrutinib 2件: 300, 331 💬
338 NF-kappa B signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
339 NF-kappa B signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
340 NF-kappa B signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
341 NOD-like receptor signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
342 NOD-like receptor signaling pathway 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
343 NOD-like receptor signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
344 NOD-like receptor signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
345 Non-alcoholic fatty liver disease 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
346 Non-alcoholic fatty liver disease 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
347 Non-alcoholic fatty liver disease 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
348 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
349 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
350 Non-small cell lung cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
351 One carbon pool by folate 💬
2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
352 One carbon pool by folate 💬
2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
353 Osteoclast differentiation 💬
1件: BTK 💬 D11422 💬 Zanubrutinib 2件: 300, 331 💬
354 Osteoclast differentiation 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
355 Osteoclast differentiation 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
356 Osteoclast differentiation 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
357 Oxytocin signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
358 Pancreatic cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
359 Pancreatic cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
360 Pancreatic cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
361 Pancreatic cancer 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
362 Parathyroid hormone synthesis, secretion and action 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
363 Parkinson disease 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
364 Parkinson disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
365 Parkinson disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
366 Pathogenic Escherichia coli infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
367 Pathogenic Escherichia coli infection 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
368 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
369 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
370 Pathogenic Escherichia coli infection 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
371 Pathogenic Escherichia coli infection 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
372 Pathways in cancer 💬
1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
373 Pathways in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
374 Pathways in cancer 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
375 Pathways in cancer 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
376 Pathways in cancer 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
377 Pathways in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
378 Pathways in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
379 Pathways in cancer 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
380 Pathways of neurodegeneration - multiple diseases 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
381 Pathways of neurodegeneration - multiple diseases 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
382 Pathways of neurodegeneration - multiple diseases 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
383 Pathways of neurodegeneration - multiple diseases 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
384 Pathways of neurodegeneration - multiple diseases 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
385 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
386 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
387 Pathways of neurodegeneration - multiple diseases 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
388 Pathways of neurodegeneration - multiple diseases 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
389 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
390 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
391 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
392 Pertussis 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
393 Pertussis 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
394 Pertussis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
395 Pertussis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
396 Phagosome 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
397 Phagosome 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
398 Phospholipase D signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
399 Phospholipase D signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
400 Phospholipase D signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
401 PI3K-Akt signaling pathway 💬
1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
402 PI3K-Akt signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
403 PI3K-Akt signaling pathway 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
404 PI3K-Akt signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
405 PI3K-Akt signaling pathway 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
406 PI3K-Akt signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
407 PI3K-Akt signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
408 PI3K-Akt signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
409 Platelet activation 💬
1件: BTK 💬 D11422 💬 Zanubrutinib 2件: 300, 331 💬
410 Platinum drug resistance 💬
2件: TOP2A, TOP2B 💬 D03899 💬 Doxorubicin 5件: 26, 28, 34, 65, 331 💬
411 Platinum drug resistance 💬
2件: TOP2A, TOP2B 💬 D00125 💬 Etoposide 11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬
412 Platinum drug resistance 💬
2件: TOP2A, TOP2B 💬 D04107 💬 Etoposide 11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬
413 Primary immunodeficiency 💬
1件: BTK 💬 D11422 💬 Zanubrutinib 2件: 300, 331 💬
414 Prion disease 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
415 Prion disease 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
416 Prion disease 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
417 Prion disease 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
418 Prion disease 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
419 Prion disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
420 Prion disease 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
421 Propanoate metabolism 💬
1件: ABAT 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
422 Prostate cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
423 Prostate cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
424 Prostate cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
425 Proteasome 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
426 Proteoglycans in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
427 Proteoglycans in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
428 Proteoglycans in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
429 Proteoglycans in cancer 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
430 Proteoglycans in cancer 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
431 Proteoglycans in cancer 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
432 Proteoglycans in cancer 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
433 Rap1 signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
434 Rap1 signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
435 Ras signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
436 Ras signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
437 Regulation of actin cytoskeleton 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
438 Relaxin signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
439 Relaxin signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
440 Renal cell carcinoma 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
441 Rheumatoid arthritis 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
442 Rheumatoid arthritis 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
443 Rheumatoid arthritis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
444 Rheumatoid arthritis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
445 Rheumatoid arthritis 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
446 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
447 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
448 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
449 Salmonella infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
450 Salmonella infection 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
451 Salmonella infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
452 Salmonella infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
453 Salmonella infection 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 4件: 26, 34, 65, 331 💬
454 Salmonella infection 💬
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 4件: 26, 34, 65, 331 💬
455 Shigellosis 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
456 Shigellosis 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
457 Shigellosis 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
458 Shigellosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
459 Shigellosis 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
460 Shigellosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
461 Sphingolipid signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
462 Sphingolipid signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
463 Sphingolipid signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
464 Spinocerebellar ataxia 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
465 Spinocerebellar ataxia 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
466 Spinocerebellar ataxia 💬
1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
467 Systemic lupus erythematosus 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
468 Systemic lupus erythematosus 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
469 Systemic lupus erythematosus 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
470 T cell receptor signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
471 T cell receptor signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
472 T cell receptor signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
473 Taurine and hypotaurine metabolism 💬
2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
474 TGF-beta signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
475 TGF-beta signaling pathway 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
476 TGF-beta signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
477 Th17 cell differentiation 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
478 Th17 cell differentiation 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
479 Th17 cell differentiation 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
480 Th17 cell differentiation 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
481 Th17 cell differentiation 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
482 Thermogenesis 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
483 Thermogenesis 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
484 Thyroid hormone signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
485 Thyroid hormone signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
486 TNF signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
487 TNF signaling pathway 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
488 TNF signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
489 TNF signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
490 Toll-like receptor signaling pathway 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
491 Toll-like receptor signaling pathway 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
492 Toll-like receptor signaling pathway 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
493 Toll-like receptor signaling pathway 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
494 Toxoplasmosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
495 Toxoplasmosis 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
496 Toxoplasmosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
497 Transcriptional misregulation in cancer 💬
1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
498 Transcriptional misregulation in cancer 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
499 Tuberculosis 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
500 Tuberculosis 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
501 Tuberculosis 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
502 Tuberculosis 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
503 Type I diabetes mellitus 💬
2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
504 Type I diabetes mellitus 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
505 Type I diabetes mellitus 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
506 Type I diabetes mellitus 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
507 Type II diabetes mellitus 💬
1件: CACNA1G 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
508 Type II diabetes mellitus 💬
1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
509 Type II diabetes mellitus 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
510 Type II diabetes mellitus 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
511 Type II diabetes mellitus 💬
1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
512 Type II diabetes mellitus 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
513 Valine, leucine and isoleucine degradation 💬
1件: ABAT 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
514 VEGF signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
515 Viral protein interaction with cytokine and cytokine receptor 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
516 Viral protein interaction with cytokine and cytokine receptor 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
517 Viral protein interaction with cytokine and cytokine receptor 💬
1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
518 Viral protein interaction with cytokine and cytokine receptor 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
519 Viral protein interaction with cytokine and cytokine receptor 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
520 Yersinia infection 💬
1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
521 Yersinia infection 💬
2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
522 Yersinia infection 💬
1件: TNF 💬 D04687 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
523 Yersinia infection 💬
1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬